Truist analyst Michael Lewis raised the firm’s price target on American Healthcare REIT to $27 from $22 and keeps a Buy rating on the shares. The firm’s updated model reflects the company’s equity offering and expected exercise of its Trilogy purchase option this year, as opposed to previously assuming exercise near the end of Q3 of FY25, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- American Healthcare REIT price target raised to $30 from $18 at JMP Securities
- American Healthcare REIT price target raised to $28 from $27 at KeyBanc
- American Healthcare REIT 17.4M share Spot Secondary priced at $23.55
- American Healthcare REIT announces offering of 14.5M shares of common stock
- American Healthcare REIT price target raised to $27 from $16 at KeyBanc